A phase II trial of pemetrexed and gemcitabine in patients with metastatic breast cancer who have received prior taxane therapy.
Pippen
John
J
USO, Texas Oncology, Baylor Sammons Cancer Center, Dallas, TX 75246, USA. john.pippen@usoncology.com
Elias
Anthony D
AD
Neubauer
Marcus
M
Stokoe
Christopher
C
Vaughn
LaTrice G
LG
Wang
Yanping
Y
Orlando
Mauro
M
Shonukan
Oluwatoyin
O
Muscato
Joseph
J
O'Shaughnessy
Joyce A
JA
Gralow
Julie
J
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D005260:Female; D005971:Glutamates / Q000008:administration & dosage / Q000009:adverse effects; D006147:Guanine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D006801:Humans; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D000068437:Pemetrexed; D016879:Salvage Therapy / Q000379:methods; D043823:Taxoids / Q000627:therapeutic use; D016896:Treatment Outcome; D000093542:Gemcitabine
D005971:Glutamates; D043823:Taxoids; D000068437:Pemetrexed; D003841:Deoxycytidine; D006147:Guanine; D000093542:Gemcitabine